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Introduction. Extremity lipomas and well-diﬀerentiated liposarcomas (WDLs) are diﬃcult to distinguish on MR imaging. We
sought to evaluate the accuracy of MRI interpretation using MDM2 ampliﬁcation, via ﬂuorescence in-situ hybridization (FISH),
as the gold standard for pathologic diagnosis. Furthermore, we aimed to investigate the utility of a diagnostic formula proposed in
the literature. Methods. We retrospectively collected 49 patients with lipomas or WDLs utilizing MDM2 for pathologic diagnosis.
Four expert readers interpreted each patient’s MRI independently and provided a diagnosis. Additionally, a formula based on
imaging characteristics (i.e. tumor depth, diameter, presence of septa, and internal cystic change) was used to predict the
pathologic diagnosis. The accuracy and reliability of imaging-based diagnoses were then analyzed in comparison to the MDM2
pathologic diagnoses. Results. The accuracy of MRI readers was 73.5% (95% CI 61–86%) with substantial interobserver agreement
(κ � 0.7022). The formula had an accuracy of 71%, which was not signiﬁcantly diﬀerent from the readers (p � 0.71). The formula
and expert observers had similar sensitivity (83% versus 83%) and speciﬁcity (64.5% versus 67.7%; p � 0.659) for detecting WDLs.
Conclusion. The accuracy of both our readers and the formula suggests that MRI remains unreliable for distinguishing between
lipoma and WDLs.

1. Introduction
Lipomas are the most common soft tissue tumor and, unless
symptomatic, do not require surgical excision or formal
surveillance when the provider is conﬁdent in the diagnosis.
However, the diﬀerence between a lipoma and welldiﬀerentiated liposarcoma (WDL) is often diﬃcult to determine based solely on imaging [1–3]. Well-diﬀerentiated
liposarcomas of the extremities have low metastatic potential
and are now also commonly referred to as atypical lipomatous tumor (ALT), reﬂecting their benign biologic behavior relative to WDLs of the mediastinum or retroperitoneum
[4]. However, given the potential for de-diﬀerentiation and
conversion to a higher grade liposarcoma, excision of these

lesions is recommended [2, 4, 5]. Thus, the distinction between lipoma and WDL/ALT is important, as asymptomatic
lipomas need no treatment or follow-up. However,
WDL/ALT of the extremity is appropriately treated with
surgical excision and postoperative surveillance. Nevertheless, the ability to distinguish between WDL/ALTand benign
lipomas using only MRI remains a diagnostic challenge.
Numerous imaging features on MRI have been reported
to facilitate diﬀerentiation between these two entities. Location deep to fascia, septations >2 mm thick, heterogeneity,
foci of high T2 signal, diameter >5 cm, stranding, nodularity,
and cystic changes within the tumor have been reported
as being more common in ALT/WDLs than in lipomas
[1, 2, 6, 7]. A representative MR image of an ALT/WDL
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Figure 1: Coronal T1 (a) and STIR (b) MRI of a 30 cm diameter ALT/WDL conﬁrmed by MDM2 FISH which is deep to fascia, contains foci
of T2 enhancement, heterogeneity, nodularity, and internal cystic changes.

demonstrating common concerning features is shown
in Figure 1. However, these features have not allowed experts
to reliably identify ALT/WDLs, and this uncertainty may
lead to unnecessary patient concern and more invasive
management.
Gaskin and Helms previously reported an accuracy of
83% in predicting the pathologic diagnosis based on MRI,
and noted that when a lesion was suspicious for ALT/WDLs,
it was more likely (64%) to represent a benign lipoma [2]
after ﬁnal pathology. O’Donnell and colleagues similarly
compared MRI evaluation between radiologists and orthopaedic oncologists, and found an accuracy of 69% in
distinguishing lipoma versus ALT/WDLs, with no diﬀerence
across specialty [1]. These studies were performed using the
World Health Organization (WHO) pathologic criteria for
diagnosis, and both recognized the need for a reproducible
method of determining the diagnosis without an invasive
surgical intervention.
The diﬃculty identifying these tumors accurately with
imaging was rendered even more complex by the fact that
the pathologic criteria for diagnosis were relatively subjective. In recent years, the gold standard for accurate
pathologic diagnosis has evolved with the discovery of
murine double minute 2 (MDM2) gene ampliﬁcation
present in all ALT/WDLs. While most ALT/WDLs may be
correctly diagnosed histologically, the atypia required may
be focal and missed on biopsy, or under/overinterpreted.
MDM2, however, is consistently ampliﬁed and its detection
using ﬂuorescence in situ hybridization (FISH) has become
the new gold standard for diagnosis [3, 8]. Using this new
diagnostic criterion, some tumors previously regarded as
lipoma are now known to be ALT/WDLs and vice versa. This
calls into question prior studies on the accuracy of MRI, as
the diagnosis based on the WHO histologic criteria may

have been incorrect. A recent study by Wang and colleagues
constructed a scoring system for diﬀerentiating lipomas
from liposarcomas utilizing MRI ﬁndings. However, this
study also utilized the WHO histologic criteria without
assessment of MDM2 ampliﬁcation, and thus the resultant
scoring system also requires further review [7].
To our knowledge, there is no study in the literature
comparing the accuracy of MRI diagnosis to the new gold
standard for pathologic diagnosis, MDM2. Therefore, the
purpose of this study is (1) to evaluate the ability of experienced readers of MR imaging to distinguish between lipoma and ALT/WDLs in the era of MDM2 FISH, (2) to
evaluate the agreement of MRI interpretations amongst
experienced readers, (3) to evaluate the utility of the diagnostic formula proposed by Wang et al., and to determine
whether or not it is able to outperform the interpretation of
fellowship-trained readers, and (4) to determine which MRI
characteristics, if any, are most predictive of the diagnosis of
ALT/WDLs. Our hypothesis was that there would be an
increase in the accuracy of MR imaging diagnosis given the
new pathologic criteria. We further hypothesized that the
weighted scoring system would provide the most accurate
and reproducible diagnosis compared to expert readers by
eliminating the inherent bias of readers to “overdiagnose”
ALT/WDLs as shown in prior studies [1, 2].

2. Materials and Methods
This study was performed in collaboration with radiology,
orthopaedic oncology, and surgical pathology. The cohort
was retrospectively collected from the institutional database
and electronic medical records were reviewed for patient
demographics, available MRI, and MDM2 pathologic diagnosis. Patients with extremity lesions superﬁcial to fascia

Sarcoma
and pathologic diagnosis based on WHO criteria were excluded from the study. Lesions outside of the extremity were
excluded in part due to the subspecialties of the readers
(orthopaedic oncology and musculoskeletal radiology).
However, they were also excluded because WDL located in
the mediastinum and retroperitoneum behave diﬀerently
than those in the extremities. Following exclusion, 49 patients with deep extremity lipomas or ALT/WDLs remained.
Each patient’s MRI was interpreted by two fellowshiptrained orthopaedic oncologists and two fellowship-trained
musculoskeletal radiologists who were blinded to the ﬁnal
diagnosis. All MR images reviewed contained T1-weighted
and T2-weighted or STIR sequences for evaluation, and all
MRI sequences were made available for reviewers at the time
of the study. All four reviewers independently interpreted
the images simultaneously, without time limitations, and
were permitted to make measurements and analyze any
desired sequence.
Readers were surveyed for each case on whether margins
were well or poorly deﬁned, tumors were homogeneous or
heterogeneous, if there was stranding or nodularity, if thick
septa >2 mm were present, or if there were cystic changes or
foci of high T2 signal. They were then asked to make a ﬁnal
imaging diagnosis of lipoma or ALT/WDL. Each categorical
variable, including the ﬁnal diagnosis, was recorded prospectively while interpreting the MR imaging.
Cohen’s Kappa coeﬃcient were used to determine the
interobserver agreement/reliability for the diagnosis and
each categorical variable (margins, homogeneity, stranding,
nodularity, thickened septa, internal cystic change, foci of
high T2 signal, and ﬁnal imaging diagnosis) for all four
expert observers. Additionally, the sensitivity, speciﬁcity,
accuracy, positive predictive value (PPV), and negative
predictive value (NPV) of the imaging diagnosis by the
expert observers were calculated based on the gold standard
MDM2 diagnosis.
Next, we used the reviewer’s responses to predict the
diagnosis using the formula published by Wang et al.
Z � 10X1 + X2 + 12X3 + 15X4 + 10X5, where X1 is gender
(0 � female; 1 � male), X2 is tumor diameter (in cm), X3 is
tumor depth (0 � superﬁcial to fascia; 1 � deep to fascia), X4
is the presence of a septum or nodule (0 � absent septum or
nodule; 1 � septum >2 mm or nodule >1 cm), and X5 is
internal cystic change (0 � no, 1 � yes). All tumors were deep
to fascia, meaning X3 was 1 for all patients included. X4 and
X5 were determined after all lesions had been reviewed and
were based on the majority opinion of the reviewers (i.e., if 2
or more expert observers felt there was a septum, nodule, or
internal cystic change, then it was considered present for the
formula). Of note, no reviewers had the formula available at
the time of their MRI interpretation. A Z score of >35 was
considered consistent with ALT/WDL as described by Wang
et al., who reported a 100% negative predictive value in their
study. Therefore, 35 was used as the cutoﬀ for testing their
formula in this study [7]. All diagnoses by the expert observers were subsequently grouped, and compared against
the diagnoses provided by the formula, using a 2-sample
paired binomial test. A p value < 0.05 was considered statistically signiﬁcant.
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Lastly, we used a stepwise regression model to select
signiﬁcant imaging predictors associated with a diagnosis of
ALT/WDL. A signiﬁcance level of 0.1 was required to allow
a proposed imaging characteristic into the model.

3. Results
Of the 49 patients included, ﬁnal pathologic diagnosis was
ALT/WDLs for 18 patients and lipoma for 31 patients. There
were six spindle cell lipomas and one lipoma with osseous
metaplasia included in the lipoma group. Pathologic diagnosis was determined by MDM2 FISH for 44 patients and
by immunohistochemistry for MDM2 and CDK4 for ﬁve
patients.
Experienced readers of MR images were unable to accurately and reliably distinguish between lipoma and
ATL/WDL on MR imaging. Collectively, the readers had an
accuracy of 73.5% based on 2 or more readers predicting
ALT/WDL. Accuracy ranged from 73.5 to 79.6% for individual observers. Expert readers showed an 83% sensitivity,
67.7% speciﬁcity, 73.5% accuracy, 60% PPV, and 87.5% NPV
for interpreting the MRI for ALT/WDL when compared to
the ﬁnal pathologic diagnosis (Table 1).
The agreement of MR interpretation between readers
was variable for each imaging characteristic; however,
agreement was substantial when choosing a ﬁnal diagnosis.
Interobserver reliability for each imaging characteristic is
shown through use of Cohen’s kappa coeﬃcient (Table 2)
with foci of high T2 signal, nodularity, and ﬁnal diagnosis
showing the most interobserver agreement. If the ﬁnal diagnosis was lipoma, MR interpreters collectively chose the
correct diagnosis 68% (21/31) of the time, whereas if the ﬁnal
diagnosis was ALT/WDL, the correct diagnosis was interpreted for 83% (15/18). There was no signiﬁcant diﬀerence in
accuracy comparing expert observers against each other or
across subspecialty (orthopaedic oncology versus musculoskeletal radiology). For the ﬁnal diagnosis, there was 100%
concordance across the four interpreters in 37/49 cases, 75%
concordance in 5/49 cases, and 50% concordance in 7/49
cases.
During investigation of the formula proposed by
Wang et al. using their advocated cutoﬀ score of 35 (>35
being considered a ALT/WDLs), we found the formula to
be less accurate than previously described. Using this
threshold, the formula had an accuracy of 71% with
sensitivity 83%, speciﬁcity 64.5%, PPV 58%, and NPV
87%. There was no signiﬁcant diﬀerence in sensitivity
(p � 1.000), speciﬁcity (p � 0.659), accuracy (p � 0.708),
PPV (p � 0.683), or NPV (p � 0.920) between the formula
and the expert interpreters. If the pathologic diagnosis
was lipoma, the formula correctly predicted the diagnosis
(score ≤ 35) only 58% (18/31) of the time, whereas if the
pathologic diagnosis was ALT/WDL, the formula correctly predicted the diagnosis (score > 35) for 83% (15/18)
of cases.
Lastly, we employed a stepwise variable selection procedure to determine which MRI features were most associated with the diagnosis of ALT/WDL. A 10% signiﬁcance
level for both selection and deletion was used to identify
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Table 1: Expert observer grouped interpretation of MRI compared to ﬁnal pathologic diagnosis.

Sensitivity
Speciﬁcity
Accuracy
Positive predictive value (PPV)
Negative predictive value (NPV)

Value
0.8333
0.6774
0.7347
0.6000
0.8750

95% CI lower bound
0.6612
0.5129
0.6111
0.4080
0.7427

95% CI upper bound
1
0.8420
0.8583
0.7920
1

Table 2: Interobserver reliability amongst four expert readers of MRI for commonly reported imaging characteristics.
Margins WD
Internal cystic Foci of high
Homogeneous Stranding Nodularity Thickened septa
Imaging diagnosis
versus PD
change
T2 signal
Kappa
0.2331
0.6122
0.4552
0.7673
0.5890
0.3333
0.7959
0.7022
p value
0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Table 3: Imaging parameter in stepwise model selection. Signiﬁcance coeﬃcient of 0.1 was required to remain in the model.
Parameter
First selection
Intercept
Margins (WD versus PD)
Homogeneous (yes versus no)
Stranding (yes versus no)
Nodularity > 1 cm (yes versus no)
Thickened septa > 2 mm (yes versus no)
Internal cystic change (yes versus no)
Foci of high T2 signal (yes versus no)
Second selection
Intercept
Foci of high T2 signal (yes versus no)

95% CI for OR
Lower
Upper

Coeﬃcient

OR

−1.091
−0.375
−0.896
0.056
0.001
−0.620
−0.186
1.142

0.472
0.167
1.118
1.002
0.289
0.689
9.822

0.097
0.010
0.079
0.155
0.019
0.036
0.906

2.290
2.720
15.732
6.486
4.290
13.098
106.436

0.154
0.352
0.209
0.934
0.998
0.367
0.805
0.060

−0.9639
1.3386

14.545

2.811

75.270

0.0215
0.0014

imaging characteristics that were signiﬁcantly correlated
with the ﬁnal pathologic diagnosis. This analysis is shown in
Table 3, and only foci of high T2 signal remains in the model
following selection, indicating that it is most strongly associated with the ﬁnal diagnosis. Foci of high T2 signal was
present in 16/18 (88.9%) ALT/WDLs and in 20/31 (64.5%)
lipomas.

4. Case Illustrations
Three cases from this cohort were selected in order to
highlight the signiﬁcance of MDM2 FISH and the diﬃcult
agreement between MRI interpretation and pathology. The
ﬁrst is the case of a 42-year-old male with a 12 cm lipomatous tumor in the left shoulder. Based on MR imaging,
4/4 expert observers, in addition to the formula (score of 34),
predicted the lesion to be a benign lipoma. Initial pathology
was concerning ALT/WDL, which was subsequently overturned following MDM2 FISH because there was no
ampliﬁcation of the MDM2 gene. The second is the case of
a 69-year-old male with a 2 cm lesion in the left arm. Again,
all four expert observers and the formula (score of 24)
predicted the lesion to be a benign lipoma, but pathology was
concerning ALT/WDL. Following MDM2 FISH, the pathologic diagnosis was subsequently conﬁrmed to be a benign

p value

lipoma, increasing the accuracy of our readers and the
formula (Figure 2).
The ﬁnal case is a 51-year-old female with a 10 cm lipomatous lesion of the right thigh. All four expert observers
predicted the lesion to be an ALT/WDL, while the formula
(with score of 22) predicted the lesion to be a benign lipoma.
Initial pathology report was read as ALT/WDL. Subsequent
MDM2 FISH was negative for gene ampliﬁcation, and given
the histologic concern for atypia, the FISH was again repeated and found to again be negative, conﬁrming the diagnosis of lipoma and changing the pathologic diagnosis
(Figure 3).

5. Discussion
Liposarcomas represent approximately 20% of all soft tissue
sarcomas and are divided into various subtypes including
atypical lipomatous tumors/well-diﬀerentiated liposarcomas
(ALT/WDLs), de-diﬀerentiated liposarcoma, myxoid liposarcoma, round cell liposarcomas, and pleomorphic liposarcomas. ALT/WDLs are often diﬃcult to distinguish
from benign lipomas on MRI [1, 2, 6, 9, 10] and have
diﬀerent treatments as well as prognosis. On MRI,
ALT/WDLs are known for having thick septa, lack of capsule
with less well-deﬁned margins, nodularity, internal cystic
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(a)

(b)

Figure 2: (a) Axial T1 MR of left shoulder with 12 cm lipomatous tumor. Formula and expert observers predicted benign lipoma, while
initial pathology was concerning ALT/WDL. Lack of MDM2 ampliﬁcation with FISH conﬁrmed a diagnosis of benign lipoma. (b) Axial T1
MR of the left arm with 2 cm lipomatous tumor. Formula and expert observers predicted benign lipoma, which was later conﬁrmed by lack
of MDM2 ampliﬁcation through FISH after initial pathology was concerning ALT/WDL.

(a)

(b)

Figure 3: (a) Coronal T1 and (b) axial STIR MR images of the right thigh lipomatous tumor. Expert observers interpreted the lesion as
heterogeneous, containing stranding, and having foci of high T2 signal. All four readers interpreted the tumor as ALT/WDL in addition to
initial pathology interpreted as ALT/WDL. MDM2 ampliﬁcation during FISH analysis conﬁrmed benign lipoma on two separate occasions,
illustrating the variability that can be seen within simple lipomas.

changes, heterogeneity, and enhancement on T2-weighted
imaging. Meanwhile, lipomas are characteristically homogeneous and encapsulated lesions composed of predominantly mature adipose tissue. However, they may
contain thin enhancing septa, be unencapsulated, or have
heterogeneity due to regions of fat necrosis, infarction or
nonfatty tissue, and creating concern for ALT/WDLs on
MRI interpretation [1, 2, 6, 9].
The importance of distinguishing between lipoma and
ALT/WDLs preoperatively is well recognized. For many
providers, ALT/WDLs receive wide local excision rather
than marginal excision to decrease the risk of local recurrence. Following surgery for ALT/WDLs, recurrence
rates vary from 13.9 to 69% [2, 11]. Lucas and colleagues,

however, found that there was a 60% local recurrence rate if
extremity tumors were treated with marginal excision,
which decreased to 11% when treated with wide local
excision [5]. The appropriate treatment remains debated,
however, as some advocate for marginal excision with or
without radiation therapy given low rates of local recurrence and the morbidity associated with wide resection
[4, 11, 12]. Importantly, many of these studies on local
recurrence rates were not based on molecular analysis for
diagnosis, and therefore, may have had inaccurate categorization of lipomatous tumors, leading to falsely low
recurrence rates if lipomas were regarded as ALT/WDLs.
Furthermore, ALT/WDLs have the potential for delayed
malignant de-diﬀerentiation and subsequent metastasis.
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Due to this potential for delayed de-diﬀerentiation as
well as the higher local recurrence rates compared to lipomas, the importance of continued surveillance postoperatively regardless of surgical margin is well established
[1, 2, 6, 11–14].
Previous publications have shown relatively poor accuracy for MRI predicting the pathologic diagnosis.
O’Donnell and colleagues found a 69% overall accuracy
for expert observers predicting the pathologic diagnosis
based on the WHO criteria, while Gaskin and Helms found
an 83% speciﬁcity and a 38% PPV [1, 2]. These studies
noted a propensity for MRI interpreters to overdiagnose
ALT/WDLs, leading to unnecessary patient worry and
more invasive surgical intervention. In an eﬀort to create
a more objective interpretation of imaging ﬁndings, Wang
and colleagues devised a scoring system based on MR
imaging features which were found to be correlated to the
ﬁnal pathologic diagnosis in their series [7]. In their study,
all ALT/WDLs had a Z score of >35 and 30/34 benign
lipomas had a Z score of ≤35. Therefore, they proposed this
scoring system as a potential alternative to invasive biopsies for preoperative decision-making. These authors,
similar to others looking at the accuracy of MRI, utilized
the WHO criteria for ﬁnal pathologic diagnosis rather than
MDM2 ampliﬁcation. Therefore, some tumors may have
been misclassiﬁed, requiring revalidation of the scoring
system.
Not only can it be diﬃcult to determine lipoma from
ALT/WDLs for the radiologist, it can also pose a challenge
to the pathologist. Histologically, the degree of atypia may
be overestimated or confounded by fat necrosis, especially
in borderline cases [3, 8]. Furthermore, tumor heterogeneity can lead to sampling error and inaccurate histologic
diagnosis. This diﬃculty can be seen in our three case
examples above, which all had concerning features on
initial pathology. With advances in modern molecular
analysis, however, the gold standard for pathologic diagnosis of ALT/WDLs has changed. Speciﬁcally, murine
double minute 2 (MDM2) has been found to be ampliﬁed
in all ALT/WDLs [10]. The use of immunohistochemistry
(IHC) for MDM2 and CDK4 has been proposed as a more
cost-eﬀective solution for determining the diagnosis and is
widely available, while FISH is typically only used at tertiary referral centers. However, for borderline cases,
MDM2 FISH has been shown to be required for accurate
pathologic diagnosis given the potential for sampling error
on biopsy and subjective interpretation of MDM2 immunohistochemistry [8, 15]. Meanwhile, MDM2 FISH has
been shown to have 100% sensitivity and speciﬁcity even on
core needle biopsy [16]. This new criterion was the focus of
the current study. The goal was to reassess the ability of
expert observers to distinguish lipoma from ALT/WDL on
MRI, given the increased accuracy of pathologic diagnosis
of these tumors using MDM2 as the gold standard. As
stated previously, 44 patients had ﬁnal pathology determined by MDM2 FISH, and 5 patients had IHC for ﬁnal
diagnosis.
Our series showed agreement amongst expert interpretation of MRI for both orthopaedic oncologists and
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musculoskeletal radiologists. Collectively, our expert observers had an accuracy of 73% for predicting the ﬁnal
pathologic diagnosis, which is consistent with prior reports.
A PPV of 60% and NPV of 87.5% indicated a tendency to
overdiagnose ALT/WDL, as reported by prior authors [1, 2].
The formula proposed by Wang et al. showed an accuracy of
71.4% with a 57% PPV and 87% NPV, slightly underperforming our expert observer’’s interpretation. This difference, however, was not statistically signiﬁcant. Unlike the
study by Wang et al., all of the tumors included in our study
were deep to fascia, making it more diﬃcult to discern lipoma from ALT/WDLs. This may account for the reduced
accuracy of the formula seen in our cohort.
Of the various MRI features tested, foci of high T2 signal
intensity had the highest correlation with a diagnosis of
ALT/WDL, unlike the study by Wang et al., which found
internal cystic change, nodules, and thick septum to be more
predictable factors [7]. However, it is important to note that
foci of high T2 signal were also present in 64.5% of benign
lipomas. This highlights the variability of these tumors and
reveals a multitude of MRI ﬁndings based on a representative cohort. This can be seen in other areas throughout the
current literature; for example, O’Donnell and colleagues
focused on stranding, nodularity, and size as the determinant factors for diagnosis [1].
We continue to understand the utility of MR imaging for
the generation of a diﬀerential diagnosis and preoperative
planning. However, based on our results, we do caution
readers that MRI should not be used in isolation for diagnosis. At this stage, despite numerous advances, we feel
that further study is required for alternative and less invasive
means of diagnosis to guide appropriate management of
these lesions preoperatively. Furthermore, we recognize that
MDM2 FISH (or MDM2/CDK4 IHC) may not be available
at all institutions, especially given its high cost. While all
lesions do not necessarily require MDM2 FISH, we agree
with Clay and colleagues that when lesions are recurrent,
deep and >10.0 cm, have equivocal atypia, and are concerning on MR imaging, they warrant investigation with
MDM2 for deﬁnitive diagnosis [3].

6. Conclusion
While MDM2 FISH has aﬀected the conﬁdence with which
pathologists can diagnose ALT/WDLs, it remains diﬃcult
for expert observers to distinguish them from benign lipomas on imaging. Based on the data presented here,
expert readers of MRI have an accuracy of 73% in distinguishing lipoma from ALT/WDL, which is consistent
with prior reports. The use of MDM2 FISH for pathologic
diagnosis, while more reliable than the WHO criteria, has
not changed the accuracy of MRI interpretation. Furthermore, the proposed scoring system by Wang et al. was
found to have less utility than previously reported, with an
accuracy of 71%. Therefore, while MRI is an important
screening tool for diﬀerentiating these lesions, pathologic
conﬁrmation with MDM2 FISH is still required for diagnostic certainty.
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